Feed / TARS

Tarsus Pharmaceuticals, Inc.

TARS

Healthcare · 72.88 +1.9% today

Participation confirmed · construction unavailableMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Tarsus Pharmaceuticals, Inc.'s move is being confirmed by its market group.

The latest filing evidence is available. 8 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.

What changed
  • Revenue increased 69.4% versus the comparable filing period.
Company+1.9% todayVolume comparison unavailable
Market group8 of 13 activeBiotechnology Therapeutics · building
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 9 of 13 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as BMRN begins moving with the group.

Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.

Watch this read

Who this business touches

The relationships behind TARS

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

LIANYFiling-linked namepartnerFeb 23, 2026

In March 2021, we entered into the China Out-License with LianBio Ophthalmology Limited (“LianBio”), granting exclusive commercial rights of TP-03 for the treatment of Demodex blepharitis and MGD within the China Territory.

MRNAModerna, Inc.partnerFeb 23, 2026

We are aware of vaccines currently under development including a multivalent recombinant protein vaccine, VLA-15, being developed by Valneva in partnership with Pfizer for Lyme disease; mRNA-based vaccine mRNA-1982/1975, being developed by Moderna and eliciti…

Depended on by

HTGCHercules Capital, Inc.investeeOct 30, 2025

The net realized gains (losses) were generated from gross realized gains of $2.8 million and $17.8 million respectively, for the three and nine month periods, primarily from the sale of our equity and warrant positions in Palantir Technologies, TransMedics Gr…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

TARS is currently a Early Follower in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.